T1	Participants 777 1214	17 sites in ten countries in North America, Europe, the Middle East, and South Africa. 50 eligible patients (aged â‰¥12 years) with homozygous familial hypercholesterolaemia, on stable lipid-regulating therapy for at least 4 weeks, and not receiving lipoprotein apheresis, were randomly allocated by a computer-generated randomisation sequence in a 2:1 ratio to receive subcutaneous evolocumab 420 mg or placebo every 4 weeks for 12 weeks.
T2	Participants 1372 1591	Patients, study personnel, and the funder were masked to treatment and to the efficacy results by the central laboratory not returning LDL cholesterol or any lipid results to the clinical sites after the baseline visit.
T3	Participants 1840 1860	50 eligible patients
